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Abstract
Polymicrobial sepsis induces organ failure and is accompanied by overwhelming inflammatory
response and impairment of microbial killing. Peroxisome proliferator-activated receptor-gamma
(PPAR-γ) is a nuclear receptor with pleiotropic effects on lipid metabolism, inflammation, and cell
proliferation. The insulin-sensitizing drugs thiazolidinediones (TZDs) are specific PPAR-γ
agonists. TZDs exert anti-inflammatory actions in different disease models, including
polymicrobial sepsis. The TZD pioglitazone, which is an FDA-approved drug, improves sepsis
outcome; however, the molecular programs that mediate the effect of pioglitazone have not been
determined. In a murine model of sepsis, we now show that pioglitazone treatment acts to improve
microbial clearance and to enhance neutrophil recruitment to the site of infection. We also
observed reduced pro-inflammatory cytokine production and high IL-10 levels in pioglitazone-
treated mice. These effects were associated with a decrease in STAT-1-dependent expression of
myeloid differentiation factor-88 (MyD88) in vivo and in vitro. IL-10R blockage abolished PPAR-
γ-mediated inhibition of MyD88 expression. These data demonstrate that the primary mechanism
by which pioglitazone protects against polymicrobial sepsis is by impairing MyD88 responses.
This appears to represent a novel regulatory program. In this regard, pioglitazone provides
advantages as a therapeutic tool, since it improves different aspects of host defense during sepsis,
ultimately enhancing survival.
INTRODUCTION
The overwhelming production of systemic inflammatory mediators is a key feature in severe
sepsis and is commonly associated with organ dysfunction and death (1). An important role
for myeloid differentiation factor (MyD88), an essential adaptor protein in the TLR/IL-1R1
signaling pathway, has been shown in the production of inflammatory mediators during
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sepsis. Myd88-deficient mice fail to produce high levels of IL-6, CXCL1, and CXCL2
during cecal ligation and puncture (CLP)-induced sepsis (2). Therefore, it should be possible
to reduce systemic inflammation by modulating MyD88 expression or activity. The
expression of MyD88 has been shown to be upregulated by lipopolysaccharide (LPS) and
inflammatory mediators such as TNF-α and IFN-γ (3) and downregulated by IL-10 (4).
Moreover, we have previously demonstrated that leukotriene B4 also induces MyD88
expression in a STAT-1-dependent manner (5).
Thiazolidinediones (TZD) are potent insulin-sensitizing drugs that function via activation of
the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ).
Pioglitazone is a TZD approved by the U.S. Food and Drug Administration used for type 2
diabetes treatment. Rosiglitazone and troglitazone also show potent insulin-sensitizing
properties, but they were removed from the market due to undesired side effects (6). In
addition to the glucose control, the activation of PPAR-γ by TZDs has also been involved in
the modulation of atherosclerosis, adipocyte proliferation and inflammation (7). Indeed,
natural and synthetic PPAR-γ ligands have been tested in experimental models of sepsis due
to their known anti-inflammatory effects. Evidences show that treatment with TZDs and
natural ligands for PPAR- γ reduces the release of IL-6, IL-10, TNF-α, CCL2 and also the
neutrophil infiltration in lung and liver induced by polymicrobial sepsis or endotoxemia (8,
9). In addition, treatment of endotoxemic mice with PPAR-γ agonists reduces levels of high
mobility group box 1 and markers for organ dysfunction. As consequence, survival of mice
is significantly increased by those treatments (8, 10–12). However, the mechanism for the
anti-inflammatory effects of PPAR-γ agonists is not fully understood. A well accepted
hypothesis is that activated PPAR-γ directly interacts with a transcription factor, resulting in
its transrepression (13). Indeed, the synthetic PPAR-γ agonist ciglitazone reduces IKK
activity and IκB degradation induced by hemorrhagic-shock (9). Along these lines, the
natural PPAR-γ agonist 15d-PGJ2 reduces IFN-α and -γ induced STAT-1 phosphorylation
in different cell types (14).
The aim of this study was to determine whether PPAR-γ impairs STAT-1 activation thereby
reducing STAT-1-dependent MyD88 expression during CLP-induced sepsis. We found that
treatment with pioglitazone, a synthetic agonist of PPAR-γ, inhibited STAT-1
phosphorylation in an IL-10R dependent manner, leading to a reduction in MyD88
expression in peritoneal cells. Pioglitazone treatment increased neutrophil migration to the
peritoneal cavity, culminating in reduced bacterial load and a reduced systemic
inflammatory response during CLP-induced sepsis.
METHODS
Mice
Female C57Bl/6 mice (8-week old, weight 18–23 g) were obtained from Jackson Laboratory
(Bar Harbor, USA). Doxycycline-controlled dnPPARγ-transgenic mice, were bred at IUSM
(15). Mice were maintained according to NIH guidelines for the use of experimental animals
with the approval of the Indiana University Committees for the Use and Care of Animals.
Sepsis induction
Sepsis was induced by CLP as previously described (16), using a 26G or 18G needle to
induce moderate or lethal sepsis, respectively. A group of mice was treated with
pioglitazone (20 mg/kg, i.p., Cayman Chemical), 18 hours before CLP surgery. Survival was
monitored at each 12 hours for 7 days after CLP surgery. At these times, mice showing signs
of imminent death (inability to maintain upright position/ataxia/tremor and/or agonal
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breathing) were euthanized. For other protocols, mice were euthanized 6 hours after CLP
surgery.
Pharmacological treatments
For in vivo experiments, pioglitazone (20 mg/Kg, i.p) was administered 1, 4 and 18 hours
before CLP surgery.
For in vitro experiments, pioglitazone, rosiglitazone, troglitazone, and GW9662 (10 μM
each, Cayman Chemical) were incubated with 2×106 cells for 24 h before immunoblotting
or PCR assays. Anti-IL-10R (Biolegend, 20 μg/mL) was incubated for 0.5 h before
pioglitazone and/or 100 ng/mL LPS (Sigma-Aldrich) stimulation.
Cell harvest
Elicited macrophages were harvested from the peritoneal cavities of mice by lavage with
PBS 4 days after the injection of 2 ml 3% thioglycollate as described previously (17).
Bacterial load
Blood was collected from the orbital plexus of mice and peritoneal cavity was washed with
PBS. Aliquots of serial log dilutions were plated in Mueller-Hinton agar dishes as
previously described (18).
Cell counts
Leukocyte numbers were determined in the peritoneal cavity and bronchoalveolar lavage
fluid (BALF) 6 h after CLP or sham using the Hemavet 950FS System.
Flow cytometry
Peritoneal cells were resuspended in PBS containing 2 mM EDTA and 0.5% FCS. Fc
receptor-mediated and nonspecific Ab binding was blocked by addition of excess CD16/
CD32 (clone 2.4G2, BD Biosciences Pharmingen) for 10 min at 4°C. The cells were stained
with mouse anti-GR1 FITC (1:100, BD Biosciences Pharmingen) for 30 min at 4°C, and the
expression of this receptor was analyzed by flow cytometry (FACSCalibur). Data were
analyzed with WinMDi and FlowJo Version 7.6.4 software.
Cytokines measurement
TNF-α, IL-10, IL-1β, and IL-6 were measured using DuoSet ELISA (R&D Systems,),
following the manufacturer's protocol.
PPAR-γ activity assay
PPAR- γ DNA binding activity in nuclear extracts (10 μg of protein) was assayed using a
PPAR-γ transcriptionfactor assay kit (Cayman Chem). For in vivo PPAR- γ activity, C57BL/
6 mice were treated or not with pioglitazone (20 mg/Kg, i.p) for 4 or 24 h and peritoneal
cells were isolated. For in vitro activity assay, WT macrophages were stimulated for 1, 4 or
24 h with 10 μM pioglitazone.
Histology
Mice were perfused with 10% formalin before lung harvesting. The tissues were fixed in
10% formalin, embedded in paraffin, cut into 5 μm sections, and stained with H&E as
previously described (19). The images were recorded using an Infinity 1 camera attached to
Nikon Eclipse Ci microscope. Capillary congestion, alveolar edema and PMN infiltration
were determined as previously described (19).
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Immunoblotting
Western blots were performed as previously described (5, 17). Protein samples were
resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with primary
antibodies against MyD88, total or phosphorylated (S727 or Y701) STAT-1, and
phosphorylated JAK2 (Tyr1007/1008) (all at 1:1000; Cell Signaling), or β-actin (1:10,000;
Sigma-Aldrich). Densitometric analysis was performed as described previously (5, 17).
RNA isolation and semiquantitative real-time RT-PCR
Total RNA from cultured cells was isolated using the Gene mammalian Total RNA
Miniprep Kit (Sigma-Aldrich) according to the manufacturer's instructions. Real-time RT-
PCR was performed as previously described (5, 17). The sequences for the primers Ppar-γ,
Ppar-α, Ppar-δ, Myd88, Stat1, and Actin (all from Integrated DNA Technologies) are listed
in Table 1. Relative expression was calculated using the comparative threshold cycle (Ct)
and expressed relative to control or WT (ΔΔCt method).
Nuclear isolation
Nuclear and cytoplasmic fractions of peritoneal cells from naïve, sham or septic mice treated
or not with pioglitazone were isolated as previously described (5) using a subcellular protein
fractionation kit according to the manufacturer's instructions (Pierce).
Statistics
Survival curves are expressed as percent survival and were analyzed by a Log-rank (Mantel-
Cox) Test. Bacterial load results are expressed as median. Other results are expressed as
mean ± SEM and were analyzed by ANOVA followed by Bonferroni analysis. Differences
were considered significant for P < 0.05.
RESULTS
Prolonged PPAR-γ activation protects mice against severe polymicrobial sepsis
PPAR-γ activation inhibits activation of TLR and NFκB, which are essential components
involved in the control of polymicrobial sepsis (20, 21). It has been shown that PPAR-γ
activation protects mice against endotoxic shock and polymicrobial sepsis (12, 22–25).
Using the cecum ligation and puncture (CLP) model, we investigated whether PPAR-γ
activation exerts different effects in vivo depending on the severity of polymicrobial sepsis.
Treatment of mice with pioglitazone (20 mg/kg) for 1 or 4 h before CLP did not have any
effect in animal survival in neither moderate nor severe sepsis (Supplemental figure 1).
When mice were treated with pioglitazone for 18 h before CLP, we observed a significant
increase in the survival of severely septic mice, but no effect on the survival of moderately
septic mice (Fig. 1A). The same protective effect was also observed in rosiglitazone-treated
mice (not shown). We found that pioglitazone treatment substantially decreased bacterial
load in severely septic mice in both peritoneal cavity (Fig. 1B) and blood (Fig. 1C). We
observed the same pattern when mice were treated with pioglitazone, followed by induction
of moderate sepsis (not shown). To determine whether expression of other classes of PPAR
was increased following pioglitazone treatment of septic animals, we performed qPCR
analysis of peritoneal cells (PCs) harvested 6 h after CLP. PPAR-γ was the most abundantly
expressed PPAR during sepsis although PPAR-α was also significantly elevated, albeit to a
much lesser extent (Fig. 1D). The increased PPAR-γ expression during CLP was confirmed
by immunoblotting (Fig. 1E). Thus, activation of PPAR-γ by pioglitazone treatment results
in further expression of PPAR-γ in septic animals. From a translational perspective, these
data demonstrate that prolonged PPAR-γ activation enhances survival of severely septic
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mice, and survival was associated with reduced bacterial load at the site of infection and in
the blood.
PPAR-γ activation increases neutrophil recruitment and decreases cytokine generation
and lung inflammation
We and others have shown that neutrophils are key cells involved in control of
polymicrobial sepsis (26–28). We also showed that high mortality in severe sepsis is a
consequence of impaired neutrophil migration to the site of infection, although neutrophils
and cytokines accumulate in other target organs (27, 29). We speculated that PPAR-γ
activation could prevent neutrophil migration failure to the peritoneal cavity during severe
sepsis, leading to enhanced microbial clearance. Our results showed a decrease in the
neutrophil numbers in the peritoneal cavity 6 h after severe sepsis and PPAR-γ activation
prevented neutrophil migration failure to the infectious site (Fig. 2A and B). The same
pattern was also observed in monocyte recruitment (not shown).
An overwhelming inflammatory response due to cytokine storm is a major cause of organ
dysfunction and death in septic patients (30, 31). We determined whether pioglitazone
treatment would inhibit the production of proinflammatory cytokines TNF-α, IL-6, and
IL-1β in septic animals. Levels of TNF-α and IL-1β in both peritoneal cavity and blood were
reduced in pioglitazone-treated septic mice when compared to untreated septic mice (Fig. 2C
and D). IL-6 levels were decreased in the blood but not in the peritoneal cavity (Fig. 2C and
D). In contrast, levels of the anti-inflammatory cytokine ɪL-10 were greatly enhanced in both
peritoneal cavity and blood in pioglitazone-treated septic mice (Fig. 2C and D). These data
suggest that pioglitazone improves mouse survival by enhancing bacterial clearance,
increasing neutrophil recruitment, and by favoring an anti-inflammatory milieu at the site of
infection.
Prolonged PPAR-γ activation decreases lung inflammation in septic mice
One of the major consequences of sepsis is the development of lung injury (27). Therefore,
one possible mechanism by which PPAR-γ improves animal survival is by decreasing the
inflammatory response in the lung. Indeed, we observed that pioglitazone treatment
inhibited accumulation of neutrophils in lungs of septic mice (Fig. 3A). We did not observe
significant changes in monocyte or lymphocyte numbers (Fig. 3A). The effect of
pioglitazone-mediated protection in the lung pathology was also confirmed by examination
of lung sections. Pioglitazone treatment decreased leukocyte recruitment to the lung, and
decreased alveolar edema and capillary congestion (Fig. 3B and C). We also detected the
presence of pro- and anti-inflammatory cytokines in the bronchoalveolar lavage fluid of
mice treated with pioglitazone (Fig 3D). The data show that pioglitazone treatment resulted
in decreased levels of TNF-α and IL-1β but dramatically increased IL-10 levels. These data
show that in addition to improving features involved in the control of microbial burden at
the site of infection, PPAR-γ activation also ameliorates lung injury, an important event
associated with mortality in sepsis (32–34).
PPAR-γ activation inhibits MyD88 expression in vivo and in vitro
We hypothesized that prolonged PPAR-γ activation inhibits inflammatory responses in
sepsis by inhibiting the expression of TLRs or the TIR adaptor MyD88, which is essential
for TLR and IL-1β receptor responsiveness (35, 36). Our data show that MyD88 expression
was decreased in peritoneal macrophages treated with different PPAR-γ agonists (Fig. 4A).
Pioglitazone and rosiglitazone were more potent than troglitazone in inhibiting MyD88
expression in macrophages. Endogenous PPAR-γ did not inhibit MyD88 expression in
macrophages from PPAR-γ DN and from WT macrophages treated with GW9662 (data not
shown). Pioglitazone treatment decreased MyD88, but not TLR4 expression in monocyte-
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derived human macrophages (Fig. 4B). Next, we investigated whether the time of PPAR-γ
activation correlates with the decrease in MyD88 expression in vivo and in vitro. Our results
show that pioglitazone enhances PPAR-γ activation 4 h after treatment in vitro and peaks
after 24 h both in vivo and in vitro (Fig. 4 C and D). We only observed a decrease in MyD88
levels 24 h after pioglitazone treatment in vivo and in vitro (Fig. 4C and D). These data
further suggest that pioglitazone-induced PPAR-activation leads to decreased MyD88 levels.
We also confirmed that pioglitazone effects are restricted to PPAR-γ activation.
Macrophages were pretreated with the PPAR-γ receptor antagonist GW9662, followed by
challenge with pioglitazone for 24 h. We did not see any changes in MyD88 expression
when macrophages were treated with GW9662 only and prevented pioglitazone-mediated
MyD88 inhibition (supplemental figure 2). We then investigated whether pioglitazone
inhibited MyD88 expression during sepsis in vivo. MyD88 expression was increased 6 h
after CLP at both the mRNA level (Fig. 4E) and protein level (Fig. 4F and G), and treatment
with pioglitazone significantly decreased MyD88 levels in these mice (Fig. 4E–G).
Activation of PPAR-γ inhibited MyD88 specifically but did not affect TLR4 expression
(Fig. 4F) or the TLR adaptor TRIF (not shown). These data indicate that PPAR-γ activation
provides an endogenous brake involved in both homeostatic and inducible MyD88
expression both in vitro and in vivo.
PPAR-γ activation inhibits serine phosphorylation and nuclear translocation of the MyD88
transcription factor STAT-1
We have previously shown that STAT-1 is the major transcription factor responsible for
MyD88 expression (37). We have also shown that the suppressor of cytokine signaling-1
(SOCS-1) inhibits MyD88 levels by preventing STAT-1 activation (37). We hypothesize
that PPAR-γ inhibits MyD88 expression by preventing STAT-1 activation. Initially, we
investigated whether PPAR-γ activation alters STAT-1 expression. No changes in STAT-1
mRNA expression were observed when macrophages were treated with pioglitazone,
rosiglitazone, troglitazone (Fig. 5A) or the PPAR-γ antagonist GW9662 (data not shown).
Furthermore, we did not observe any changes in STAT-1 mRNA levels in macrophages
from PPAR-γ receptor DN mice (data not shown). In vivo experiments showed that while
STAT-1 expression was increased after sepsis, pioglitazone did not affect STAT-1 levels in
vivo (Fig. 5B). Since no changes in STAT-1 expression were observed, we speculated that
PPAR-γ might alter phosphorylation of STAT-1 at the residue important for DNA binding
activity (Y701) or at the site required for maximal transcriptional activity (S727) (38–40).
We found that phosphorylated Y701 was not detected under any conditions tested (not
shown), but we found that peritoneal cells from septic mice exhibited higher STAT-1 S727
phosphorylation than peritoneal cells from sham mice (Fig. 5C). Pioglitazone treatment
inhibited STAT-1 S727 phosphorylation compared to septic mice (Fig. 5C). Since SOCS-1
inhibits JAK/STAT-1 activation, we sought to determine the levels of SOCS-1 in
pioglitazone-treated mice during sepsis. No differences in SOCS-1 expression were detected
in any group tested (not shown). Furthermore, the decrease in STAT-1 phosphorylation was
not dependent on JAK-2 phosphorylation (Fig. 5D). Even though sepsis increased JAK-2
phosphorylation, pioglitazone treatment did not decrease JAK-2 phosphorylation (Fig. 5D).
To further investigate the molecular programs involved in PPAR-γ-mediated STAT-1
action, we investigated whether PPAR-γ activation influenced STAT-1 nuclear translocation
in vivo. Peritoneal cells from septic mice exhibited enhanced STAT-1 nuclear translocation,
an event prevented by PPAR-γ activation (Fig. 5E). These data suggest that PPAR-γ
activation decreases MyD88 expression by preventing two important steps involved in
STAT-1 activation— serine phosphorylation and nuclear translocation.
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PPAR-γ-induced IL-10 accounts for the inhibition of MyD88 expression in macrophages
Since we previously observed that pioglitazone treatment greatly enhances IL-10 levels in
vitro and in vivo (41–44) and coupled with the fact that IL-10 decreases MyD88 expression
(4, 45), we speculated that IL-10 mediates PPAR-γ effects on MyD88 levels. We determined
whether pioglitazone enhanced IL-10 production and whether it further enhanced LPS-
induced IL-10 levels in thioglycollate-elicited macrophages. We found that pioglitazone
significantly enhanced IL-10 production in elicited macrophages and amplified LPS-induced
IL-10 levels (Fig. 6A). To investigate whether enhanced IL-10 in pioglitazone-treated cells
accounted for inhibition of MyD88, macrophages were pretreated with anti-IL-10 receptor
antibody, followed by pioglitazone and LPS treatment for 24 h to further investigate the role
of PPAR-γ and IL-10 in inducible MyD88 expression. Pioglitazone inhibited LPS actions
(Fig. 6B). However, when cells were pretreated with anti-IL10R, we observed an
enhancement in MyD88 levels, which occurred even in the presence of pioglitazone (Fig.
6B). We further investigated whether blocking IL-10 actions would also prevent PPAR-γ-
inhibition of STAT-1 activation. As we observed during CLP, macrophage treatment with
pioglitazone decreased LPS-induced STAT-1 S727 phosphorylation but not STAT-1 Y701
phosphorylation, an event mediated by endogenous IL-10 actions (Fig. 6B). These results
are consistent with the existence of a novel regulatory program in which PPAR-γ activation
enhances IL-10 levels to decrease STAT-1-dependent MyD88 expression, which further
inhibits TIR-dependent macrophage activation and improves animal survival during sepsis
(Fig. 6C).
DISCUSSION
This study demonstrates the therapeutic potential of the PPAR-γ ligand pioglitazone in the
most widely used models of sepsis and septic shock, which resemble human sepsis in many
parameters (31, 46, 47). Specifically, we demonstrate that prolonged PPAR-γ activation
protects mice against severe CLP-induced sepsis by ameliorating important steps in the
pathogenesis of sepsis which leads to increased survival, including: 1) restoring neutrophil
recruitment to the site of infection, 2) increasing bacterial clearance at the site of infection
and in blood, 3) decreasing cytokine storm, and 4) inhibiting MyD88 expression and,
therefore, the actions of TIR (Toll-IL-1 receptor) domains, such as members of the
Interleukin-1 Receptor and Toll-Like Receptor Superfamily. Importantly, these results
suggest a novel PPAR-γ /IL-10 network that inhibits MyD88 levels in macrophages that
dampens systemic inflammatory response.
Most PPAR- γ agonists belong to the TZD family (6, 48). These compounds are currently
used in the treatment of type 2 diabetes and some cardiovascular complications. Since
pioglitazone is currently FDA-approved for treatment of type-2 diabetes, we decided to use
only pioglitazone in our study. Rosiglitazone and pioglitazone have been beneficial in
treating various kidney injuries including nephropathy resulting from diabetes, hypertension,
and cyclosporine-induced renal injury (6); however the consequences of chronic TZD intake
on host defense systems remain to be determined.
That PPAR-γ activation decreases inflammatory responses in different disease models is
well established (6, 13, 25). In the CLP model, PPAR-γ activation improves animal survival,
and the mechanisms underlying animal protection are diverse (25). Zingarelli, et. al., showed
that 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) and ciglitazone protects rats against polymicrobial
sepsis by inhibiting activation of two inflammatory transcription factors, NFκB and AP-1,
and improving hemodynamic performance (8). Furthermore, 15d-PGJ2 treatments also
improve renal, liver, and pancreatic function in LPS-challenged mice (10). PPAR-γ
activation also inhibits the expression/activation of different inflammatory mediators
involved in the pathogenesis of sepsis, including reactive oxygen and nitrogen intermediates,
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gelatinase B, and cyclooxygenase 2 (25, 49). Here, we also observed that pioglitazone
treatment decreases the generation of pro-inflammatory cytokines responsible for the
cytokine storm such as IL-1β, TNF-α and IL-6. These cytokines are involved in the
infiltration of neutrophils, leading to tissue necrosis and favoring overwhelming
inflammatory response (27, 29). We did not observe an effect of endogenous PPAR-γ
activation in the control of sepsis, since treatment of mice with the PPAR-γ antagonist
before severe CLP did not alter animal survival or bacterial load (not shown). Other
laboratories have reported that PPAR-γ antagonist or PPAR-γ deficient mice are protected
from CLP, which is somewhat contradictory to our findings (24, 49, 50). The reasons for
such discrepancy include severity of the CLP, time of treatment, mouse strain, and species
differences (rat vs. mice).
An important finding in our study is that in addition to improving local inflammatory
responses, we also observed that pioglitazone prevented acute lung injury in septic mice.
This amplified response, also called cytokine storm, results in systemic inflammation that
affects several organs, including lungs (51). The lung is particularly affected, and acute lung
injury secondary to sepsis is characterized by edema, inflammatory cell infiltration, and
impaired gas exchange that can lead to multi-organ failure (30, 52). PPAR-γ activation
inhibited CLP-induced edema formation and neutrophil recruitment to the lung, and
inhibited cytokine production favoring leukocyte activation. Our findings are in agreement
with laboratories that have reported that PPAR-γ activation decreases neutrophils
sequestration in lung and production of proinflammatory cytokines (9, 53).
We have previously demonstrated the involvement of TLRs in the inflammatory cytokines
production and systemic activation of neutrophils in sepsis. Mice lacking TLR2, TLR4 or
TLR9 show attenuated systemic inflammatory response and reduced mortality rates under
polymicrobial sepsis (24, 26, 28, 54). These effects were due to enhanced bacterial load
control in the knockout mice as consequence of the reduced systemic activation of
neutrophils and increased recruitment of these cells to the infection site (24, 26, 28, 54).
Based on that, we speculate that the overwhelming inflammatory response triggered by the
recognition of diverse ligands to specific TLRs in polymicrobial sepsis can be modulated by
the partial abrogation of TLRs signaling. Here we demonstrate that pioglitazone and other
TZDs specifically decrease mRNA and protein levels of MyD88, the main adaptor protein
of TLRs, in both naïve macrophages and cells from septic mice. Therefore, it can be
suggested that pioglitazone-induced decrease of MyD88 expression dampens the excessive
TLR signaling, improving the outcome to polymicrobial sepsis.
MyD88 expression is controlled by different transcription factors including NFκB (55), IL-6
responsive elements (56), and STAT-1 (37). We speculated that PPAR-γ activation would
decrease STAT-1 activation leading to inhibition of MyD88 levels. PPAR-γ inhibition of
STAT-1 DNA binding activity in IFN-α and β activated cells was previously reported (57,
58). However, PPAR-γ inhibition of STAT-1 activity in vivo and in a sepsis model or in
LPS-stimulated macrophages remains to be determined. Our data show that PPAR-γ
activation impairs both upstream effects of STAT-1, such as nuclear translocation, and
phosphorylation of STAT-1 on the S727 residue, which is required for optimal
transcriptional activity (59). The intracellular molecular programs involved in PPAR-γ
regulation of different steps involved in STAT-1 activation remain to be investigated.
PPAR-γ activation elicits numerous anti-inflammatory programs by impairing activation of
different transcription factors such as NFκB, AP-1, and STAT-1 through the sequestration
of essential, shared co-activators (13). A well-known STAT-1 inhibitor is the suppressor of
cytokine signaling-1 (SOCS1) (60, 61). We did not detect any changes in SOCS1 levels
when mice or cells were treated with pioglitazone (data not shown). Park et al., have shown
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that rosiglitazone and 15d-PGJ2 inhibit activation of JAK2 and STAT-1 in glia cells and
astrocytes in a manner independent of PPAR-γ activation (57). Furthermore, PPAR-γ
activation may enhance the expression of other members of the SOCS family, such as
SOCS2 and SOCS3, which could inhibit the JAK/STAT-1 pathway. However, such events
remain to be determined. The discrepancy between the work of Park and our current
findings could be due to different agonists used, cell types, and inflammatory stimuli. In
addition to the direct anti-inflammatory effect of pioglitazone, PPAR- γ activation also
enhanced the secretion of anti-inflammatory molecules, such as IL-10 (62, 63). We found
that pioglitazone alone enhanced basal and LPS-induced IL-10 in macrophages in vitro and
in the peritoneal cavity and blood of septic mice. IL-10 is known to decrease TLR responses
and, more specifically, MyD88 expression (4) in macrophages. In addition, it has also been
shown that IL-10 inhibits IFN-γ and LPS-induced STAT-1 activation in different cell types
(64, 65). Therefore, we speculated that IL-10 is a key component in the PPAR-γ inhibition
of STAT-1 activation and, consequently, MyD88 expression. Our data show that blocking
IL-10R action prevents pioglitazone-mediated inhibition of STAT-1 S727 phosphorylation
and MyD88 expression. The fact that IL-10 mediates anti-inflammatory actions of PPAR-γ
has been shown in different inflammatory models, such as allergic asthma and ischemia-
reperfusion (62, 63). However, the molecular programs involved in IL-10 mediated S727
STAT-1 phosphorylation that further inhibits MyD88 levels remain to be determined. The
signaling programs involved in PPAR-γ-induced IL-10 production are currently a topic of
intensive research in our laboratory.
Our findings suggest the existence of a novel regulatory program elicited by PPAR-γ
activation involving IL-10 production that inhibits STAT-1-dependent MyD88 expression.
Importantly, changes in MyD88 levels were critical in preventing cytokine storm, which in
turn improved animal survival, reduced bacterial load, and reduced neutrophil recruitment to
the lungs, all of which are key components involved in sepsis protection. Thus, in view of
the fact that pioglitazone is currently used to treat type 2 diabetes, this drug represents a
potential new therapeutic approach to treating overwhelming inflammatory conditions
observed in septic patients.
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Fig. 1. Pioglitazone treatment enhances animal survival and microbial clearance in
polymicrobial sepsis
(A) Survival rates of C57BL/6 mice (n = 10 per group) treated with 20 mg/Kg pioglitazone
for 18 h before severe or moderate CLP-induced sepsis. The survival rate was determined at
each 12 h up to 7 days after surgery. *P < 0.05. Colony-forming units (CFU) in peritoneal
cavity (B) or blood (C) 6 h after CLP in C57BL/6 mice treated or not with pioglitazone 18 h
prior to CLP. (D) Ppar-γ, -δ, -α mRNA expression in the peritoneal cells 6 h after CLP or
Sham determined by qPCR as described in Material and Methods. (E) PPAR-γ or actin
protein expression detected by immunoblotting of peritoneal cells harvested 6 h after CLP or
sham. Numbers under lanes indicate the relative density of PPAR-γ determined from
densitometric analysis and expressed as the mean ± SEM from three individual experiments.
Values of the WT control group were set as 100%. Data are expressed as mean ± SEM from
at least three independent experiments; *P < 0.05 relative to the sham group or CLP vs
pioglitazone treatment.
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Fig. 2. PPAR-γ enhances neutrophil recruitment to the site of infection and decreases pro-
inflammatory cytokine production
(A) C57BL/6 were pretreated or not with pioglitazone for 18 h and subjected to severe CLP
or sham and after 6 h peritoneal neutrophil numbers were determined using Hemavet as
described in the Material and Methods. (B) Mice were treated as in A and the number of
GR1+ cells were determined by FACS. (C) C57BL/6 mice were treated as in A followed by
determination of the levels of TNF-α, IL-6, IL-1β and IL-10 in the peritoneal lavage fluid by
ELISA. (D) Mice were treated as in A and serum was harvested 6 h after CLP for detection
of TNF-α, IL-6, IL-1β and IL-10 by ELISA. Data are mean ± SEM; *P < 0.05 vs. sham
group, #P < 0.05 pioglitazone-treated mice vs. untreated.
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Fig. 3. Pioglitazone treatment decreases inflammatory response in the lung
(A) leukocyte recruitment (neutrophil, monocytes and lymphocytes) in C57BL/6 mice
treated or not with pioglitazone for 18 h followed by CLP. Leukocytes present in the BAL:
neutrophils, monocytes, and lymphocytes were determined using Hemavet, 6 h after CLP
surgery. (B) Histological sections stained with H&E from mice treated as in A. (C) Lung
histology scores: alveolar edema, capillary congestion, and polymorphonuclear neutrophil
(PMN) infiltration were determined as described in Material and Methods. (D) Cytokine
concentrations in BAL: IL-1β, TNF-α IL-6, and IL-10 were determined by ELISA. n = 6–8
in each group. Data are mean ± SEM; *P < 0.05 vs. sham group, #P < 0.05 pioglitazone-
treated mice vs. untreated.
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Fig. 4. PPAR-γ inhibits expression of MyD88 in vitro and in vivo
(A) Peritoneal macrophages were treated with 10 μM of PPAR-γ agonists: rosiglitazone,
pioglitazone, troglitazone for 24 h, followed by determination of MyD88 and Actin
expression by qPCR as described in Materials and Methods. (B) Monocyte-derived human
macrophages were treated with pioglitazone for 24h and subjected to immunoblot for
MyD88, TLR4 and Actin. Numbers under lanes indicate the relative density of PPAR-γ,
determined from densitometric analysis and expressed as the mean ± SEM from three
individual experiments, with the values of the untreated group set as 100% control. (C)
Macrophages were treated with pioglitazone for the indicated time points and the expression
of MyD88 and Actin mRNA was determined by qPCR and PPAR-γ activity was determined
as described in Material and Methods. (D) C57BL/6 mice (n=3 per time point) were treated
with 20 mg/Kg pioglitazone via intraperitoneal injection for the indicated time points and
the expression of MyD88 and Actin mRNA was determined by qPCR and PPAR-γ activity
was determined in the peritoneal cells as described in Material and Methods. (E–G) C57BL/
6 mice were treated with pioglitazone for 18 h followed by CLP surgery. Peritoneal cells
from 3 different mice were harvested 6 h after induction of sepsis, lysed, and subjected to
qPCR (E) immunoblotting (F) for determination of MyD88, TLR4 and Actin. (G)
Densitometric analysis of the bands shown in D. Data are mean ± SEM; *P < 0.01 vs. sham
group or control group, and #P < 0.01 pioglitazone-treated mice vs. untreated.
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Figure 5. PPAR-γ inhibits STAT-1 nuclear translocation and transcriptional activity
(A) Peritoneal macrophages were treated with 10 μM of PPAR-γ agonists: rosiglitazone,
pioglitazone, troglitazone for 24 h, followed by determination of STAT-1 and Actin
expression by qPCR as described in Material and Methods. (B–E) C57BL/6 mice were
treated or not with pioglitazone for 18 h followed by CLP surgery. Peritoneal cells were
harvested 6 h after sepsis induction, lysed, and subjected to qPCR for determination of
STAT-1 expression and immunoblotting for determination of total STAT-1, STAT1 pS727
(D), or JAK2, laminin and Actin (E). The numbers underneath the bands represent mean
densiometric analysis of the bands shown. Data are mean ± SEM; *P < 0.01 vs. sham group,
and #P < 0.01 pioglitazone-treated mice vs. untreated.
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Figure 6. IL-10 mediates PPAR-γ inhibition of STAT-1 dependent MyD88 expression
(A) TG-elicited peritoneal macrophages were treated or not with pioglitazone for 18 h,
followed by LPS stimulation for 24 h. IL-10 in the supernatant was measured by ELISA.
Data are mean ± SEM; *P < 0.05 vs. untreated cells, #P < 0.05 vs. LPS-challenged. (B)
Cells were pretreated with anti-IL-10R (20 μg/mL) for 0.5 h before the addition of 10 μM
pioglitazone for 24 h and before LPS stimulation for another 24 h. Cell lysates were
subjected to immunoblotting for MyD88, STAT-1 pS727, STAT-1 pY701, and Actin. The
numbers underneath the bands represent mean densiometric analysis of the bands shown.
Data are representative of two independent experiments. (C) Proposed model of PPAR-γ
regulation of IL-10 and MyD88 expression and enhancement of animal survival after CLP
procedure.
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Table 1
Target Forward Reverse
ppar α ACTCCACCTGCAGAGCAACCA TAGATCTCCTGCAGTAGCGGG
ppar δ CCCTGGCAAAGCATTTGTAT AATCCTTGGCCCTCTGAGAT
ppar γ TTGAGCCCAAGTTCGAGTTTGCTG ATTCTAGAGCCCGCAGAATGGTGT
myd88 TAGTCGCAGACAGTGATGAAC CTGCAGAGCAAGGAATGTGA
stat1 GATCACTCTTTGCCACAACCA TAGAGCATGAAATCAAGAGCCT
β actin CTGCCTGACGGCCAAGTC CAAGAAGGAAGGTCGGAAAAGAG
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